[Therapeutic angiogenesis for ischemic diseases].
The clinical consequences of peripheral arterial disease include pain on walking, pain at rest and loss of tissue integrity in the distal ischemic limbs. Although development of beneficial drugs and intervention devices do contribute to the treatment of this disease, critical limb ischemia is estimated to develop in 500 to 1,000 individuals per million per year. As angiogenic growth factors can stimulate the development of collateral arteries, a concept called "therapeutic angiogenesis" is now evaluated in the clinical fields. Recent progress in molecular biology has led to the development of gene therapy as a new strategy to treat a variety of cardiovascular diseases using angiogenic growth factors such as vascular endothelial growth factor (VEGF). Therapeutic angiogenesis using angiogenic growth factors is expected to be a new treatment for patients with severe ischemic heart or peripheral arterial disease.
Aoki
Motokuni
M
Department of Geriatric Medicine, Osaka University Graduate School of Medicine.
Morishita
Ryuichi
R
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000628:therapy*; D016503:Drug Delivery Systems; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D017228:Hepatocyte Growth Factor / Q000627:therapeutic use*; D006801:Humans; D017202:Myocardial Ischemia / Q000628:therapy*; D018919:Neovascularization, Physiologic / Q000235:genetics* / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*
D043925:Angiogenesis Inducing Agents; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors; D017228:Hepatocyte Growth Factor